FX-909 is a covalent cancer[1].
FX-909 (0.03-1 mg/kg; BID for 21 days) 在 UMUC9 UC 异种移植小鼠模型中显示出抗癌作用[1]。
[1]. Mertz J A, et al. Development of a surrogate tissue pharmacodynamic (PD) assay for clinical use with FX-909, a novel inhibitor of the urothelial luminal lineage transcription factor peroxisome proliferator-activated receptor gamma (PPARG). Cancer Research, 2023, 83(7_Supplement): 2802-2802.
















